Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XW8Y
|
|||
| Drug Name |
CNTX-4975
|
|||
| Indication | Knee osteoarthritis [ICD-11: FA01; ICD-10: M15-M19, M47; ICD-9: 715] | Phase 3 | [1] | |
| Pain [ICD-11: MG30-MG3Z] | Phase 3 | [2] | ||
| Morton neuroma [ICD-11: 8C11.6; ICD-10: G57.6] | Phase 2 | [2] | ||
| Company |
Centrexion Therapeutics Boston, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03660943) A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.